Insulin Therapy Lowers Haemoglobin Levels, but Most Patients Don't Reach Goal: Presented at ADA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Insulin Therapy Lowers Haemoglobin Levels, but Most Patients Don't Reach Goal: Presented at ADA

By Ed Susman

ORLANDO, Fla -- June 27, 2010 -- In the real-life setting, initiation of insulin in patients with type 2 diabetes reduces glycated haemoglobin (Hb A1C) levels, but most patients still have levels above goal, researchers reported here at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA).

"Results at 1 year are encouraging, but the majority of participants -- about 68% -- remain above the American Diabetes target goal of Hb A1C of <7%," said Nick Freemantle, PhD, University of Birmingham, Edgbaston, United Kingdom, on June 26.

He noted that after 1 year of treatment, fasting blood glucose and postprandial blood glucose remain elevated. He said that while the glucose levels were reduced from baseline the persistence of higher than goal levels suggests "that there may have been suboptimal insulin dose titration over the first year."

Researchers enrolled 3,031 patients to observe treatment outcomes among patients with type 2 diabetes in real-world settings from 314 clinical practices.

At baseline, patients had a mean Hb A1C of 9.5%, which after 1 year of insulin therapy, was reduced to a mean of 7.7% (P < .001).

Fasting blood glucose decreased from 207.9 mg/dL at baseline to 142.2 mg/dL after a year (P < .001). Postprandial blood glucose decreased from 256.2 to 173.1 mg/dL after a year of therapy (P < .001).

However, mean change in body weight increased from 79.9 kg to a mean of 81.3 kg, also significant (P < .001).

Dr. Freemantle said that small changes in low-density lipoprotein cholesterol indicated "that physicians are focused on glucose control rather than on intense lipid lowering for potential cardiovascular risk reduction."

Funding for this study was provided by sanofi-aventis.

[Presentation title: Insulin Initiation in People With Type 2 Diabetes Mellitus (T2DM) in Real Life Practice - 1-Year (yr) Results of the 4-yr CREDIT Study. Abstract 0623-P]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities